Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Long noncoding RNA Malat1 regulates differential activation of macrophages and response to lung injury.

Cui H, Banerjee S, Guo S, Xie N, Ge J, Jiang D, Zörnig M, Thannickal VJ, Liu G.

JCI Insight. 2019 Feb 21;4(4). pii: 124522. doi: 10.1172/jci.insight.124522. eCollection 2019 Feb 21.

2.

FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation.

Steiner M, Schneider L, Yillah J, Gerlach K, Kuvardina ON, Meyer A, Maring A, Bonig H, Seifried E, Zörnig M, Lausen J.

PLoS One. 2019 Jan 17;14(1):e0210515. doi: 10.1371/journal.pone.0210515. eCollection 2019.

3.

The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.

Hoang VT, Verma D, Godavarthy PS, Llavona P, Steiner M, Gerlach K, Michels BE, Bohnenberger H, Wachter A, Oellerich T, Müller-Kuller U, Weissenberger E, Voutsinas JM, Oehler VG, Farin HF, Zörnig M, Krause DS.

Leukemia. 2019 Jul;33(7):1700-1712. doi: 10.1038/s41375-018-0358-8. Epub 2019 Jan 11.

PMID:
30635626
4.

Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation.

Debaize L, Jakobczyk H, Avner S, Gaudichon J, Rio AG, Sérandour AA, Dorsheimer L, Chalmel F, Carroll JS, Zörnig M, Rieger MA, Delalande O, Salbert G, Galibert MD, Gandemer V, Troadec MB.

Nucleic Acids Res. 2018 Nov 30;46(21):11214-11228. doi: 10.1093/nar/gky756.

5.

Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury.

Kölling M, Genschel C, Kaucsar T, Hübner A, Rong S, Schmitt R, Sörensen-Zender I, Haddad G, Kistler A, Seeger H, Kielstein JT, Fliser D, Haller H, Wüthrich R, Zörnig M, Thum T, Lorenzen J.

Sci Rep. 2018 Feb 21;8(1):3438. doi: 10.1038/s41598-018-21720-3.

6.

Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.

Khageh Hosseini S, Kolterer S, Steiner M, von Manstein V, Gerlach K, Trojan J, Waidmann O, Zeuzem S, Schulze JO, Hahn S, Steinhilber D, Gatterdam V, Tampé R, Biondi RM, Proschak E, Zörnig M.

Biochem Pharmacol. 2017 Dec 15;146:53-62. doi: 10.1016/j.bcp.2017.10.003. Epub 2017 Oct 13.

PMID:
29031818
7.

Delayed Mesoderm and Erythroid Differentiation of Murine Embryonic Stem Cells in the Absence of the Transcriptional Regulator FUBP1.

Wesely J, Steiner M, Schnütgen F, Kaulich M, Rieger MA, Zörnig M.

Stem Cells Int. 2017;2017:5762301. doi: 10.1155/2017/5762301. Epub 2017 May 15.

8.

Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors.

Hauck S, Hiesinger K, Khageh Hosseini S, Achenbach J, Biondi RM, Proschak E, Zörnig M, Odadzic D.

Bioorg Med Chem. 2016 Nov 15;24(22):5717-5729. doi: 10.1016/j.bmc.2016.09.015. Epub 2016 Sep 14.

PMID:
27729195
9.

Dietary restriction improves repopulation but impairs lymphoid differentiation capacity of hematopoietic stem cells in early aging.

Tang D, Tao S, Chen Z, Koliesnik IO, Calmes PG, Hoerr V, Han B, Gebert N, Zörnig M, Löffler B, Morita Y, Rudolph KL.

J Exp Med. 2016 Apr 4;213(4):535-53. doi: 10.1084/jem.20151100. Epub 2016 Mar 7.

10.

Single-Stranded DNA-Binding Transcriptional Regulator FUBP1 Is Essential for Fetal and Adult Hematopoietic Stem Cell Self-Renewal.

Rabenhorst U, Thalheimer FB, Gerlach K, Kijonka M, Böhm S, Krause DS, Vauti F, Arnold HH, Schroeder T, Schnütgen F, von Melchner H, Rieger MA, Zörnig M.

Cell Rep. 2015 Jun 30;11(12):1847-55. doi: 10.1016/j.celrep.2015.05.038. Epub 2015 Jun 18.

11.

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.

Harter PN, Jennewein L, Baumgarten P, Ilina E, Burger MC, Thiepold AL, Tichy J, Zörnig M, Senft C, Steinbach JP, Mittelbronn M, Ronellenfitsch MW.

PLoS One. 2015 May 19;10(5):e0127123. doi: 10.1371/journal.pone.0127123. eCollection 2015.

12.

Targeting Disease Persistence in Gastrointestinal Stromal Tumors.

Ordog T, Zörnig M, Hayashi Y.

Stem Cells Transl Med. 2015 Jul;4(7):702-7. doi: 10.5966/sctm.2014-0298. Epub 2015 May 1.

13.

FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors.

Schwamb B, Pick R, Fernández SB, Völp K, Heering J, Dötsch V, Bösser S, Jung J, Beinoraviciute-Kellner R, Wesely J, Zörnig I, Hammerschmidt M, Nowak M, Penzel R, Zatloukal K, Joos S, Rieker RJ, Agaimy A, Söder S, Reid-Lombardo KM, Kendrick ML, Bardsley MR, Hayashi Y, Asuzu DT, Syed SA, Ordog T, Zörnig M.

Int J Cancer. 2015 Sep 15;137(6):1318-29. doi: 10.1002/ijc.29498. Epub 2015 Mar 12.

14.

A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.

Kramer D, Schön M, Bayerlová M, Bleckmann A, Schön MP, Zörnig M, Dobbelstein M.

Cell Death Dis. 2015 Feb 12;6:e1634. doi: 10.1038/cddis.2015.17.

15.

Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.

Malz M, Bovet M, Samarin J, Rabenhorst U, Sticht C, Bissinger M, Roessler S, Bermejo JL, Renner M, Calvisi DF, Singer S, Ganzinger M, Weber A, Gretz N, Zörnig M, Schirmacher P, Breuhahn K.

Hepatology. 2014 Oct;60(4):1241-50. doi: 10.1002/hep.27218. Epub 2014 Jul 31.

PMID:
24824848
16.

Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth.

Michalik KM, You X, Manavski Y, Doddaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S.

Circ Res. 2014 Apr 25;114(9):1389-97. doi: 10.1161/CIRCRESAHA.114.303265. Epub 2014 Mar 6.

PMID:
24602777
17.

EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.

Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zörnig M, Zender L, Dombrowski F, Evert M, Schirmacher P, Longerich T.

Hepatology. 2014 May;59(5):1886-99. doi: 10.1002/hep.26954. Epub 2014 Mar 27.

18.

Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.

Baumgarten P, Harter PN, Tönjes M, Capper D, Blank AE, Sahm F, von Deimling A, Kolluru V, Schwamb B, Rabenhorst U, Starzetz T, Kögel D, Rieker RJ, Plate KH, Ohgaki H, Radlwimmer B, Zörnig M, Mittelbronn M.

Neuropathol Appl Neurobiol. 2014 Feb;40(2):205-16. doi: 10.1111/nan.12088.

PMID:
24117486
19.

A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes.

Eißmann M, Schwamb B, Melzer IM, Moser J, Siele D, Köhl U, Rieker RJ, Wachter DL, Agaimy A, Herpel E, Baumgarten P, Mittelbronn M, Rakel S, Kögel D, Böhm S, Gutschner T, Diederichs S, Zörnig M.

PLoS One. 2013 May 22;8(5):e64873. doi: 10.1371/journal.pone.0064873. Print 2013.

20.

The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells.

Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S.

Cancer Res. 2013 Feb 1;73(3):1180-9. doi: 10.1158/0008-5472.CAN-12-2850. Epub 2012 Dec 14.

21.

Complexome profiling identifies TMEM126B as a component of the mitochondrial complex I assembly complex.

Heide H, Bleier L, Steger M, Ackermann J, Dröse S, Schwamb B, Zörnig M, Reichert AS, Koch I, Wittig I, Brandt U.

Cell Metab. 2012 Oct 3;16(4):538-49. doi: 10.1016/j.cmet.2012.08.009. Epub 2012 Sep 13.

22.

Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development.

Eißmann M, Gutschner T, Hämmerle M, Günther S, Caudron-Herger M, Groß M, Schirmacher P, Rippe K, Braun T, Zörnig M, Diederichs S.

RNA Biol. 2012 Aug;9(8):1076-87. doi: 10.4161/rna.21089. Epub 2012 Aug 1.

23.

Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.

Eißmann M, Melzer IM, Fernández SB, Michel G, Hrabě de Angelis M, Hoefler G, Finkenwirth P, Jauch A, Schoell B, Grez M, Schmidt M, Bartholomae CC, Newrzela S, Haetscher N, Rieger MA, Zachskorn C, Mittelbronn M, Zörnig M.

Oncogene. 2013 May 16;32(20):2586-91. doi: 10.1038/onc.2012.263. Epub 2012 Jul 2.

PMID:
22751129
24.

The Apaf-1-binding protein Aven is cleaved by Cathepsin D to unleash its anti-apoptotic potential.

Melzer IM, Fernández SB, Bösser S, Lohrig K, Lewandrowski U, Wolters D, Kehrloesser S, Brezniceanu ML, Theos AC, Irusta PM, Impens F, Gevaert K, Zörnig M.

Cell Death Differ. 2012 Sep;19(9):1435-45. doi: 10.1038/cdd.2012.17. Epub 2012 Mar 2.

25.

Palmitoylation of human FasL modulates its cell death-inducing function.

Guardiola-Serrano F, Rossin A, Cahuzac N, Lückerath K, Melzer I, Mailfert S, Marguet D, Zörnig M, Hueber AO.

Cell Death Dis. 2010 Oct 21;1:e88. doi: 10.1038/cddis.2010.62.

26.

Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain.

Lückerath K, Kirkin V, Melzer IM, Thalheimer FB, Siele D, Milani W, Adler T, Aguilar-Pimentel A, Horsch M, Michel G, Beckers J, Busch DH, Ollert M, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Staal FJ, Rajalingam K, Hueber AO, Strobl LJ, Zimber-Strobl U, Zörnig M.

Blood. 2011 Jan 13;117(2):519-29. doi: 10.1182/blood-2010-07-292722. Epub 2010 Oct 22.

PMID:
20971954
27.

Mcl-1-mediated impairment of the intrinsic apoptosis pathway in circulating neutrophils from critically ill patients can be overcome by Fas stimulation.

Paunel-Görgülü A, Zörnig M, Lögters T, Altrichter J, Rabenhorst U, Cinatl J, Windolf J, Scholz M.

J Immunol. 2009 Nov 15;183(10):6198-206. doi: 10.4049/jimmunol.0901264. Epub 2009 Oct 19.

28.

Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth.

Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL, Zörnig M.

Hepatology. 2009 Oct;50(4):1121-9. doi: 10.1002/hep.23098.

29.

The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells.

Kirkin V, Cahuzac N, Guardiola-Serrano F, Huault S, Lückerath K, Friedmann E, Novac N, Wels WS, Martoglio B, Hueber AO, Zörnig M.

Cell Death Differ. 2007 Sep;14(9):1678-87. Epub 2007 Jun 8.

30.

The CD95 receptor: apoptosis revisited.

Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zörnig M, Lynch DH.

Cell. 2007 May 4;129(3):447-50.

31.

Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.

Wichmann C, Chen L, Heinrich M, Baus D, Pfitzner E, Zörnig M, Ottmann OG, Grez M.

Cancer Res. 2007 Mar 1;67(5):2280-9.

32.
33.

Regulation of FasL expression: a SH3 domain containing protein family involved in the lysosomal association of FasL.

Qian J, Chen W, Lettau M, Podda G, Zörnig M, Kabelitz D, Janssen O.

Cell Signal. 2006 Aug;18(8):1327-37. Epub 2005 Nov 28.

PMID:
16318909
34.

Fas ligand is localized to membrane rafts, where it displays increased cell death-inducing activity.

Cahuzac N, Baum W, Kirkin V, Conchonaud F, Wawrezinieck L, Marguet D, Janssen O, Zörnig M, Hueber AO.

Blood. 2006 Mar 15;107(6):2384-91. Epub 2005 Nov 10.

PMID:
16282344
35.

Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL.

Baum W, Kirkin V, Fernández SB, Pick R, Lettau M, Janssen O, Zörnig M.

J Biol Chem. 2005 Dec 2;280(48):40012-24. Epub 2005 Oct 4.

36.

Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells.

Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L, Werz O, Eikel D, Zörnig M, Nau H, Fleming I, Doerr HW, Cinatl J Jr.

Cell Death Differ. 2006 Mar;13(3):446-53.

37.

Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.

Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, Joos S, Zörnig M.

Gut. 2006 Feb;55(2):234-42. Epub 2005 Aug 23.

41.

The role of Bcl-2 family members in tumorigenesis.

Kirkin V, Joos S, Zörnig M.

Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49. Review.

42.

HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma.

Brezniceanu ML, Völp K, Bösser S, Solbach C, Lichter P, Joos S, Zörnig M.

FASEB J. 2003 Jul;17(10):1295-7. Epub 2003 May 20.

PMID:
12759333
43.

Apoptosis regulators and their role in tumorigenesis.

Zörnig M, Hueber A, Baum W, Evan G.

Biochim Biophys Acta. 2001 Oct 1;1551(2):F1-37. Review.

PMID:
11591448
44.
45.

The human homologue (GFI1B) of the chicken GFI gene maps to chromosome 9q34.13-A locus frequently altered in hematopoietic diseases.

Rödel B, Wagner T, Zörnig M, Niessing J, Möröy T.

Genomics. 1998 Dec 15;54(3):580-2. No abstract available.

PMID:
9878267
46.
47.

Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis.

Hueber AO, Zörnig M, Lyon D, Suda T, Nagata S, Evan GI.

Science. 1997 Nov 14;278(5341):1305-9.

48.

Human Bak induces cell death in Schizosaccharomyces pombe with morphological changes similar to those with apoptosis in mammalian cells.

Ink B, Zörnig M, Baum B, Hajibagheri N, James C, Chittenden T, Evan G.

Mol Cell Biol. 1997 May;17(5):2468-74.

49.

Cell cycle: on target with Myc.

Zörnig M, Evan GI.

Curr Biol. 1996 Dec 1;6(12):1553-6. Review.

50.

Supplemental Content

Loading ...
Support Center